Literature DB >> 23237556

Tumor-stromal interactions in pancreatic cancer.

Clifford Whatcott1, Haiyong Han, Richard G Posner, Daniel D Von Hoff.   

Abstract

The tumor associated stroma has been described in recent years as being complicit in tumor growth in pancreatic cancer. The stroma hosts a variety of components of both cellular and molecular makeup. In normal tissues, the stroma provides nutrients and regulatory signals for proper cellular polarity and function. However, following oncogenic transformation, the stromal compartment is conscripted to provide stimulatory signals and protection to tumor cells. It is these tumor-stromal interactions that are currently of great therapeutic interest. Several key reports have suggested that therapeutic targeting of the tumor-stromal interactions in pancreatic cancer has the potential to offer survival benefit. In this review, we will discuss the tumor-stromal interactions that contribute to tumor growth and progression, and ways in which we might counter these interactions.

Entities:  

Mesh:

Year:  2013        PMID: 23237556      PMCID: PMC3632415          DOI: 10.1615/critrevoncog.v18.i1-2.80

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  113 in total

1.  Denileukin diftitox for the treatment of panniculitic lymphoma.

Authors:  Karen S McGinnis; Michael Shapiro; Jacqueline M Junkins-Hopkins; Mitchell Smith; Stuart R Lessin; Carmela C Vittorio; Alain H Rook
Journal:  Arch Dermatol       Date:  2002-06

2.  Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).

Authors:  Rakhshandra Talpur; Narin Apisarnthanarax; Staci Ward; Madeleine Duvic
Journal:  Leuk Lymphoma       Date:  2002-01

3.  Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.

Authors:  Russell D Leek; Kate L Talks; Francesco Pezzella; Helen Turley; Leticia Campo; Nicholas S Brown; Roy Bicknell; Marian Taylor; Kevin C Gatter; Adrian L Harris
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

4.  Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas.

Authors:  Tina W f Yen; Nils Petter Aardal; Mary P Bronner; David R Thorning; Christopher E Savard; Sum P Lee; Richard H Bell
Journal:  Surgery       Date:  2002-02       Impact factor: 3.982

Review 5.  Integrin signalling during tumour progression.

Authors:  Wenjun Guo; Filippo G Giancotti
Journal:  Nat Rev Mol Cell Biol       Date:  2004-10       Impact factor: 94.444

6.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.

Authors:  Yu-An Yang; Oksana Dukhanina; Binwu Tang; Mizuko Mamura; John J Letterio; Jennifer MacGregor; Sejal C Patel; Shahram Khozin; Zi-Yao Liu; Jeffrey Green; Miriam R Anver; Glenn Merlino; Lalage M Wakefield
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

7.  Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

Authors:  Rebecca S Muraoka; Nancy Dumont; Christoph A Ritter; Teresa C Dugger; Dana M Brantley; Jin Chen; Evangeline Easterly; L Renee Roebuck; Sarah Ryan; Philip J Gotwals; Victor Koteliansky; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

8.  Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression.

Authors:  Hiroshi Tazawa; Futoshi Okada; Tokushige Kobayashi; Mitsuhiro Tada; Yukiko Mori; Yoshie Une; Fujiro Sendo; Masanobu Kobayashi; Masuo Hosokawa
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

9.  Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins.

Authors:  Hidenori Miyamoto; Tatsuya Murakami; Kunihiro Tsuchida; Hiromu Sugino; Hidenori Miyake; Seiki Tashiro
Journal:  Pancreas       Date:  2004-01       Impact factor: 3.327

10.  Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Authors:  Udaya K Liyanage; Todd T Moore; Hong-Gu Joo; Yoshiyuki Tanaka; Virginia Herrmann; Gerard Doherty; Jeffrey A Drebin; Steven M Strasberg; Timothy J Eberlein; Peter S Goedegebuure; David C Linehan
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

View more
  35 in total

1.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

2.  Interaction between cancer cells and cancer-associated fibroblasts after cisplatin treatment promotes cancer cell regrowth.

Authors:  Shoshi Hisamitsu; Tomoyuki Miyashita; Hiroko Hashimoto; Shinya Neri; Masato Sugano; Hiroshi Nakamura; Shota Yamazaki; Atsushi Ochiai; Koichi Goto; Masahiro Tsuboi; Genichiro Ishii
Journal:  Hum Cell       Date:  2019-08-22       Impact factor: 4.174

3.  Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer.

Authors:  Marcela D'Alincourt Salazar; Edwin R Manuel; Weimin Tsai; Massimo D'Apuzzo; Leanne Goldstein; Bruce R Blazar; Don J Diamond
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

4.  miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.

Authors:  Hardik R Mody; Sau Wai Hung; Rakesh K Pathak; Jazmine Griffin; Zobeida Cruz-Monserrate; Rajgopal Govindarajan
Journal:  Mol Cancer Res       Date:  2017-04-03       Impact factor: 5.852

5.  Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Jason Castle; Spiros Kotopoulis; Flemming Forsberg
Journal:  Methods Mol Biol       Date:  2020

6.  Using Gold Nanoparticles To Disrupt the Tumor Microenvironment: An Emerging Therapeutic Strategy.

Authors:  Jilian R Melamed; Rachel S Riley; Danielle M Valcourt; Emily S Day
Journal:  ACS Nano       Date:  2016-12-01       Impact factor: 15.881

7.  c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell line HPAC in a Ca-switch model.

Authors:  Takumi Konno; Takafumi Ninomiya; Takayuki Kohno; Shin Kikuchi; Norimasa Sawada; Takashi Kojima
Journal:  Histochem Cell Biol       Date:  2014-12-16       Impact factor: 4.304

8.  Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model.

Authors:  Weijing Cai; Ranjala Ratnayake; Michael H Gerber; Qi-Yin Chen; Yichao Yu; Hartmut Derendorf; Jose G Trevino; Hendrik Luesch
Journal:  Invest New Drugs       Date:  2018-08-03       Impact factor: 3.850

Review 9.  Macromolecular therapeutics.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

10.  IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.

Authors:  Hongyu Zhou; Weiping Qian; Fatih M Uckun; Liya Wang; Y Andrew Wang; Hongyu Chen; David Kooby; Qian Yu; Malgorzata Lipowska; Charles A Staley; Hui Mao; Lily Yang
Journal:  ACS Nano       Date:  2015-08-10       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.